The use of anti-BRAF drugs (vemurafenib or dabrafenib) associated or not with anti-MEK therapy (trametinib or cobimetinib), has considerably improved progression-free and overall survival for patients bearing mutated V600 metastatic melanoma [4, 17]. Here, MAP2K7 is linked to metastatic melanoma.